Management of Hypertension in Pregnancy

Comparison of Safety Profiles

The American College of Cardiology and other guidelines recommend labetalol as a first-line agent for hypertension management during pregnancy due to its better safety profile and fewer adverse fetal effects 1, 2, 3
Labetalol has combined alpha-1 and non-selective beta-blocking properties, providing more balanced blood pressure control 4
Labetalol is associated with minimal risk of fetal growth restriction, with no reports of teratogenicity 2
The European Society of Cardiology considers labetalol safe and effective for intravenous treatment of severe pre-eclampsia 5

Propranolol is not specifically recommended in pregnancy guidelines for hypertension management due to its higher risks of fetal growth restriction, neonatal bradycardia, and neonatal hypoglycemia 1, 3, 6, 7
The non-selective beta-blocking properties of propranolol without alpha blockade may lead to unopposed alpha-mediated vasoconstriction 4

The European Heart Journal recommends starting dose of labetalol typically 100-200 mg twice daily, can be titrated up to 1200 mg daily in divided doses, and may need more frequent dosing due to accelerated drug metabolism during pregnancy 2
For severe hypertension requiring IV treatment, the American College of Cardiology recommends starting with 10-20 mg IV, can be titrated up to 300 mg 4
Monitor for potential side effects including bronchospasm, bradycardia, and postural hypotension 4

Labetalol is contraindicated in patients with second or third-degree AV block, maternal systolic heart failure, and use with caution in women with asthma 4
The goal of antihypertensive treatment during pregnancy is to prevent severe hypertension while allowing the fetus more time to mature, with a target blood pressure of SBP 140-150 mmHg and DBP 90-100 mmHg 5, 7